Citations

Clear

79 citation(s) found for "Shang, Lu".

Epstein-Barr virus-associated multiple sclerosis: recent mechanistic advances and clinical therapeutic perspectives
Cheng, Ruogu, Y, Gao , Zheng, Ruoyi , Wen, Muzi, Li, Gaoling, Pan, Wenbin, Liao, Yuqiao, Wen, Linxin , Hu, Yueyang, Zhao-Fleming, Hannah , Shang, Pei , Wen, Muzi

Mayo Clinic

Frontiers in Immunology | May 21, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1799161 | PMID 42253989 Get It

Multiple sclerosis (MS) is an immune-mediated chronic inflammatory and degenerative disease of the central nervous system (CNS). Typically occurring in young and middle-aged individuals, untreated MS can have high rates of disability and recurrence, thereby imposing a significant burden on the patient, their family, and society. Many factors are implicated in the etiology of MS, with the relationship between Epstein-Barr Virus (EBV) infection and the development of MS being the subject of extensive research recently. When the human body experiences a decline in immune function, it may trigger reactivation of EBV, and this reactivation is also believed to increase the risk of onset or relapse of MS. Currently, the phenomenon of cross-reactivity resulting from molecular mimicry following EBV infection (including reactivation status) is theorized as a contributing etiology. EBV-mediated abnormalities in T cells and B cells also play a key role in the development of MS. However, the underlying mechanisms have not been thoroughly understood. Meanwhile, the limited availability of effective treatment options for MS, in particular MS progression, underscores the urgent need for novel therapeutic strategies. Here, we discuss the pathophysiological mechanisms underlying MS, specifically emphasizing the relationship between EBV infection and the disease pathology. Furthermore, we introduced relevant pharmacological targets in order to propose a broader range of therapeutic alternatives for individuals diagnosed with MS.
Editorial: Neuroinflammation in postoperative cognitive dysfunction and related disorders
Li, Ying, Xiao, Jie, Zhu, Mingqin , Shang, Pei

Mayo Clinic

Frontiers in Anesthesiology | May 18, 2026 | Volume: 5 | Issue: No issue available | Pages: No page available

10.3389/fanes.2026.1807728 Get It

Intensive care unit acquired weakness: an update in the context of respiratory virus infection
Zheng, Ruoyi , Lin, Mingkai, Wen, Muzi, Shang, Pei , Shang, Pei , Zhang, Hongliang

Mayo Clinic

Expert Review of Clinical Immunology | May 16, 2026 | Volume: 22 | Issue: 5 | Pages: 481-497

10.1080/1744666x.2026.2672491 | PMID 42140750 Get It

First in human evidence of autonomically-mediated immune dysfunction after spinal cord injury
Solinsky, Ryan, Hareland, Kimberly, Veith, Daniel, Overlee, Brittany, Shang, Pei , Clarkson, Ben, Howe, Charles, Solinsky, Ryan , Veith, Daniel D. , Overlee, Brittany L., Howe, Charles L.

Mayo Clinic

Physiology | May 12, 2026 | Volume: 41 | Issue: S1 | Pages: No page available

10.1152/physiol.2026.41.s1.2345659 Get It

Study objective: To characterize physiologic autonomic dysfunction in humans after chronic spinal cord injury (SCI) relative to uninjured controls and to identify autonomic correlates to neuroimmune deficits. Hypothesis: Individuals with greater autonomic dysfunction after SCI will have more pronounced immune dysfunction, which will be further influenced by sympathetically mediated increases in catecholamine levels. Methodology: Both uninjured controls and individuals with SCI completed a battery of autonomic physiology tests aimed at characterizing preservation of supralesional/sublesional sympathetic activation and global sympathetic inhibition. The autonomic testing battery included 3-minute hand and foot cold pressor tests, 3 Valsalva maneuvers with goal expiratory pressure of 30 mmHg, a novel bladder pressor test (5 minutes of sustained bladder pressure at 35 cmH20 with room temperature sterile water infusion), paced breathing at 0.25 Hz for heart rate/blood pressure variability, and successive doses of bolus intravenous phenylephrine (Oxford technique). A subset of individuals in both cohorts had baseline and cold pressor stressed levels of catecholamines/cortisol drawn and immunologic assessments. Peripheral blood mononuclear cells were extracted from this baseline sample and assessed with flow cytometry for cellular exhaustion markers (CD69, PD-1, TIGIT, TIM-3). Antigen recall response, with/without primed exposure of catecholamines was also completed to identify how sympathetic activation variably impacted functional immune performance with exposure to viral peptides. Data: n=35 uninjured controls; n=29 individuals with SCI Summary of Results: When compared to uninjured controls, individuals with SCI demonstrated significant autonomic dysfunction in all three domains, with decreased supralesional sympathetic activation (Valsalva pressure recovery time, p< 0.0001), abnormal sublesional sympathetic activation (increased bradycardia, p< 0.0001), and impaired sympathetic inhibition (larger dose/body-weight adjusted increase in mean arterial pressure, p=0.0006). As expected, autonomic dysfunction in those with SCI existed on a continuum, with some having largely normal autonomic regulation and others exhibiting profound deficits. Principal component analysis confirmed these three domains as the primary drivers of variability. Cellular exhaustion markers were increased in those with SCI, with positive correlation (R2=0.42) between degree of global autonomic dysfunction (Z-score over 2.0) and CD3+ CD8+ T-cell TIM-3 immunologic exhaustion markers. Antigen recall response was impaired in those with SCI and autonomic dysfunction on physiologic testing, with pronounced decrement in response when catecholamines were added (mean 57% of response lost in CD69 T-cells to Epstein-Barr virus antigen exposure, 53% lost to Flu antigen). Conclusions: In humans with SCI, early evidence supports that individuals have greater autonomic dysfunction and that this is correlated to increased immunologic deficits. Funding Sources: NIH K23HD102663, R01NS115126 This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Regulation and Mechanistic Insight of Traditional Chinese Medicine Techniques on Gut Microbiota: A Visual Analysis and Data Mining Approach
Zou, Bing-Qian, Shang, Ming-Ming, Wang, J , Zhang, Xin-Yue, Moossavi, Maryam , Ma, Xueling

Mayo Clinic

World Journal of Traditional Chinese Medicine | February 11, 2026 | Volume: 12 | Issue: 1 | Pages: 96-112

10.4103/wjtcm.wjtcm_54_25 Get It

Context: Traditional Chinese medicine (TCM) techniques, grounded in TCM theory, offer flexible and personalized therapeutic strategies. Increasing evidence indicates that gut microbiota dysbiosis is closely associated with the onset and progression of various diseases, highlighting a complex mutual relationship. Investigating the interaction between TCM techniques and gut microbiota may provide both a theoretical and practical foundation for clinical application. However, comprehensive systematic analyses remain limited. Objective: This study aimed to identify core themes and emerging trends in research on the interactions between TCM techniques and gut microbiota. In addition, it sought to explore underlying correlations using data mining approaches to provide insights supporting clinical applications and mechanistic studies. Materials and Methods: A systematic literature review was conducted using the Web of Science Core Collection and China National Knowledge Infrastructure for bibliometric analysis. Co-occurrence analysis was performed using CiteSpace software to identify research characteristics and development trends. Key data were extracted and visualized through an interactive network diagram generated with Cytoscape. Results: Current research predominantly focuses on acupoint application, moxibustion, and TCM enema, all of which exhibit significant effects in promoting beneficial microbiota and suppressing pathogenic strains. The regulatory impact of these TCM techniques on gut microbiota is closely associated with inflammatory response pathways and immunity. Conclusions: TCM techniques are extensively applied in disease management. Among them, moxibustion, acupoint application, TCM enema, and Tuina remain prominent and evolving areas of interest. Further empirical research is warranted to elucidate the biological mechanism underpinning these effects within the guidance of TCM pattern theory.
Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 irak
Liao, Aijun , Xia, Zhongjun, Liu, Jing , Cen, Hong , Xu, Yan , Li, Fei , Zhong, Yuping , Ito, Satoshi, Togano, Tomiteru , Fang, Baijun , Sun, Chunyan , Jing, Hongmei, Ri, Masaki , Kitano, Toshiyuki , Shimazaki, Chihiro , Ito, Shigeki , Fu, Rong, Komeno, Takuya, Teisserenc, Florence Suzan, Gao, Dan , Li, Yi , Lu, Jin , Dou, Xuelin , Li, Chunrui , Wang, Yafei, Xia, Zhongjun , Cen, Hong, Ishida, Tadao , Sun, Chunyan, Jing, Hongmei , Sunami, Kazutaka , Jin, Jie , Fu, Rong , Matsue, Kosei , Huang, Shang‐Yi , Ailawadhi, Sikander , Wang, Xu , Liu, Gang

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5819-5819

10.1182/blood-2025-5819 Get It

Abstract Background: Intravenous (IV) isatuximab plus pomalidomide and dexamethasone (Isa-Pd) is approved for treatment in patients with relapsed/refractory multiple myeloma (RRMM) based on the ICARIA-MM study. Subcutaneous (SC) administration of Isa offers potential advantages such as shorter administration duration and greater patient comfort compared with IV routes. Isa SC via an on-body injector (OBI), an investigational wearable bolus injector, demonstrated safety and efficacy in a Phase 1b study in patients with RRMM. The IRAKLIA trial (NCT05405166) was the first Phase 3 trial evaluating the non-inferiority of Isa-Pd SC via an OBI vs Isa-Pd IV in patients with RRMM. Here, we report the findings of the IRAKLIA trial in the East Asian subgroup with RRMM. Methods: This global, multicenter, open-label study enrolledpatients aged ≥18 years with RRMM who had received ≥1 prior line of therapy (LOT) including lenalidomide and a proteasome inhibitor (PI). Patients were randomized 1:1 to Isa SC (1400 mg) or Isa IV (10 mg/kg) weekly in Cycle (C)1, then every 2 weeks in addition to P (4 mg orally daily, Day [D]1-21) and d (40 mg orally [20 mg if age ≥75 years] weekly). Treatment was administered in 4-week cycles and continued until disease progression, unacceptable toxicity, or patient withdrawal. Co-primary endpoints included overall response rate (ORR) and observed Isa concentration before dosing (Ctrough) at steady state (predose at C6D1). Key secondary endpoints included rate of very good partial response or better (≥VGPR), Ctroughlevel Cycle 2 Day 1 (C2D1), infusion reaction incidence, and patient satisfaction rate based on the patient experience and satisfaction questionnaire (PESQ) at C5D15. Results: The East Asian subgroup consisted of 105 patients from China (Mainland, n=82 and Taiwan, n=1) and Japan(n=22) (SC, n=50; IV, n=55). Baseline characteristics of the East Asian subgroup were generally balanced between the two arms and generally comparable to the overall global population (median age 62 years; median 2 prior LOT; 29.5% high-risk cytogenetics; 82.9% refractory to lenalidomide; 7.6% prior exposure to daratumumab). After a median of 13.0 months follow-up, ORR in the SC and IV arm was 74.0% and 70.9%, respectively (relative risk [95% CI] = 1.044 [0.815 – 1.335]). The mean (SD) of Ctroughat C6D1 was 502 (232) µg/mL for SC arm and 282 (123) µg/mL for IV arm. The geometric mean ratio (90% CI) comparing SC to IV for Ctrough at steady state was 1.756 (1.346 – 2.290). The ≥VGPR rates were 58.0% for SC and 50.9% for IV (relative risk [95% CI] = 1.139 [0.798 – 1.631]). The mean(SD) of C2D1 Ctroughlevel was 420 (161) µg/mL for the SC arm and 262 (111) µg/mL for IV arm. The geometric mean ratio (90% CI) comparing SC to IV for Ctrough at C2D1 was 1.673 (1.321 to 2.120). The infusion reaction incidence was 0% and 21.8% for SC and IV, respectively. Grade ≥3treatment-emergent adverse events were observed in 82.0% and 87.3% of patients in the SC and IV arms, respectively. Treatment discontinuation rates were 6% for the SC arm and 12.7% for the IV arm. Injection site reactions (ISRs) occurred in 4% (2/50) of patients in the SC arm and in 0.21% (2/964) of SC injections (all Grade 1), with 99.3% of SC injections completed successfully. Isa SC patients expressed higher satisfaction with their injection method, with 64.0% of patients reporting “satisfied” or “very satisfied” vs 52.7% of Isa IV patients (odds ratio [95% CI] = 1.594 [0.728 – 3.489]). Conclusions: The efficacy, safety and pharmacokinetic results between Isa SC vs IV + Pd in the East Asian population from the IRAKLIA study were consistent with the results of the overall global population, in which non-inferiority of ORR, Ctrough at C6D1, ≥VGPR and Ctrough at C2D1 was demonstrated and statistically significantly fewer infusion reactions and higher patient satisfaction were also noted for SC vs IV. These results support the potential use of Isa SC delivered via OBI in East Asian patients and demonstrate the potential of this delivery method to improve patient experience and practice efficiency.
Identification of HLA-restricted GAD65-specific CD8+ T cell Responses in Patients with GAD65 Antibody-associated Disorders 9147
Shang, Pei, Pucci, Susanna, Overlee, Brittany, Shrestha, Ramila Barun, Sagen, Jessica, Mohler, Morgan, Pittock, Sean, Howe, Charles L., Clarkson, Ben D. S., Shang, Pei, Pucci, Susanna, Overlee, Brittany, Shrestha, Ramila Barun, Sagen, Jessica, Mohler, Morgan, Pittock, Sean, Howe, Charles L., Clarkson, Ben D. S.

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.2588 Get It

Abstract Description Background Glutamic acid decarboxylase 65 (GAD65) antibodies are found in patients with stiff-person syndrome (SPS), cerebellar ataxia (CA), epilepsy and type-I diabetes (T1D). Given the intracellular localization of the antigenic target, a direct pathogenic role for GAD65 antibody (GAD65Ab) is unlikely. Methods PBMC-derived dendritic cells (DCs) from GAD65Ab+ patients with SPS (n = 6), epilepsy (n = 4), CA (n = 5), or T1D (n = 4) were pulsed with full-length GAD65 proteins or with 15-mer peptides from GAD65. T cell activation, exhaustion, and cytotoxicity were measured via cytometric bead array, FluoroSpot, flow cytometry, and live cell imaging. Results CD8+ T cells from patients with GAD65Ab-associated neurological disorders (AD) were activated by exposure to DCs pulsed with full-length GAD65 (p &lt; 0.01 vs unstimulated, Mann-Whitney test; n = 16). We found 3 peptides of interest that caused a 10-30% increase in activated CD8+ T cells in GAD65AbAD patients, as assessed by surface CD69+ labeling. Using NetMHCpan4.2, we identified 8 different 9-mer peptides with high predicted affinity for HLA-C*03:03/04 and HLA-C*07:01/02. Two of these peptides showed high binding to HLA-C and subsequently demonstrated tetramer labeling of CD8+ T cells in GAD65AbAD patients. Conclusions We demonstrated that both full-length GAD65 protein and specific GAD peptides activated CD8+ T cells derived from patients with GAD65AbAD, indicating a potential pathogenic role for these effectors in these disorders. Funding Sources Support from Aditxt Immune Health Project (EU CT number: 2023-504798-19-00) and the Center for MS and Autoimmune Neurology in Mayo Clinic. Topic Categories Neuroimmunology (NEUR)
Nuclear DAB2IP regulates DNA replication initiation through activating PLK1-mediated HBO1 phosphorylation
Shang, Zeng‐Fu , Yu, Lan , Newman, Ciara , Chen, Wei‐Min , Birdsong, Grant W, Sharp, Brett C, Story, Michael D. , Saha, Debabrata , Davis, Anthony J. , Davis, Anthony J , Saha, Debabrata

Mayo Clinic

Nucleic Acids Research | November 20, 2025 | Volume: 53 | Issue: 21 | Pages: No page available

10.1093/nar/gkaf1179 | PMID 41261855 Get It

Abstract DAB2IP (Disabled homolog 2 interacting protein), a recognized tumor suppressor, plays a pivotal role in regulating various oncogenic pathways. Our previous research demonstrated that DAB2IP functions as a cell cycle regulator by facilitating PLK1-mediated mitosis progression. Here, we elucidate a novel function of DAB2IP in promoting DNA replication origin firing. Mechanistically, we identified that DAB2IP localizes to the nucleus, where it interacts with the histone acetyltransferase HBO1 and enhances the HBO1–PLK1 interaction. DAB2IP facilitates PLK1-mediated phosphorylation of HBO1, which subsequently promotes HBO1-directed acetylation of histone 3 at lysine 14 (H3K14Ac). This modification enables the loading of the minichromosome maintenance protein (MCM) complex onto chromatin, thereby supporting DNA replication and maintaining genome integrity. Additionally, we found that ATR regulates CDK1-mediated phosphorylation of DAB2IP, and that this phosphorylation is essential for the formation and activation of the HBO1-PLK1 complex. Ablation of DAB2IP phosphorylation results in increased genomic instability due to incomplete replication of genomic DNA, as evidenced by the accumulation of anaphase ultrafine bridges and 53BP1 nuclear bodies in G1 phase of the cell cycle. In summary, our findings underscore the critical regulatory role of DAB2IP in DNA replication initiation and genomic stability maintenance, providing new insights into its function in cellular homeostasis.
Large language models for bioinformatics
Ruan, Wei, Lyu, Yanjun , Zhang, Jing , Cai, Jiazhang , Lu, Yao , Wang, Tao , Liu, Yufang , Fang, Luyang , Liu, Ziyu , Liu, Zhengliang , Li, Yiwei , Wu, Zihao , Chen, Junhao , Jiang, Hanqi, Yang, Zhenyuan, Liang, Shizhe, Zhang, Wei , Ma, Terry, Dou, Yuan , Zhang, Jianli , Gong, Xinyu , Gan, Qi , Zou, Yusong , Chen, Z. J. , Qian, Yuanxin, Yu, Shuo , Song, Kenan, Sikora, Andrea, Li, Xiang , Wang, Yingfeng , Zhong, Wenxuan, Liu, Rongjie , Huang, Chao , Shen, Ye , Yan, Yajun , Liu, Tianming, Huang, Chao , Song, Kenan , Wang, Peilong, Chen, Jingyuan, Song, Kenan , Ruan, Wei, Shu, Peng , Yang, Ge , Gao, Shang , Wang, Yue , Wang, Peilong , Zhao, Lin , Jiang, Hanqi , Pan, Yi Feng , Chen, Jingyuan , Dou, Yuan, Chen, Z. J. , Qian, Yuanxin, Jin, Lu , Wang, Xianqiao , Sikora, Andrea , Li, Gang , Li, Quanzheng , Zhang, Lu, Abate, Yohannes , He, Lifang , Zhong, Wenxuan, Liu, Wei , Ma, Ping , Zhu, Hongtu , Zhu, Dajiang

Mayo Clinic

Quantitative Biology | September 29, 2025 | Volume: 14 | Issue: 1 | Pages: No page available

10.1002/qub2.70014 | PMID 41676319 Get It

Abstract With the rapid advancements in large language model technology and the emergence of bioinformatics‐specific language models (BioLMs), there is a growing need for a comprehensive analysis of the current landscape, computational characteristics, and diverse applications. This survey aims to address this need by providing a thorough review of BioLMs, focusing on their evolution, classification, and distinguishing features, alongside a detailed examination of training methodologies, datasets, and evaluation frameworks. We explore the wide‐ranging applications of BioLMs in critical areas such as disease diagnosis, drug discovery, and vaccine development, highlighting their impact and transformative potential in bioinformatics. We identify key challenges and limitations inherent in BioLMs, including data privacy and security concerns, interpretability issues, biases in training data and model outputs, and domain adaptation complexities. Finally, we highlight emerging trends and future directions, offering valuable insights to guide researchers and clinicians toward advancing BioLMs for increasingly sophisticated biological and clinical applications.